

ECOP 2018 resolution on the Future of Oncology Pharmacy 2025



Members of the European Society of Oncology Pharmacy (ESOP) **believe**:

- science, technology and social trends have continually driven evolution and development in the role and services of the pharmacy profession, from the first establishment of pharmacy premises in the Middle Ages, to the first pharmacopoeia ushered in by the scientific and industrial revolution, and into the modern era, with rise of developments such robotic pharmacy and internet pharmacy;
- External trends impacting pharmacy and promoting change can be confidently predicted to be a constant in the next decade, with 'the fourth industrial revolution' likely to see further technological breakthroughs and 'mainstreaming' of them in to practice across a number of fields, including but not limited to:
 - robotics,
 - artificial intelligence,
 - nanotechnology,
 - quantum computing,
 - biotechnology,
 - the Internet of Things,
 - the Industrial Internet of Things (IIoT)
 - fifth-generation wireless technologies (5G),
 - additive manufacturing/3D printing,
 - fully autonomous vehicles and machines.

Members of the European Society of Oncology Pharmacy (ESOP) therefore **resolve** to:

- predict and respond early to technological and scientific drivers of change impacting oncology pharmacy to ensure that their potential to achieve better outcomes for cancer patients is leveraged and secured; and,
- ensure the expertise and experience of the oncology pharmacy profession is recognised and heard by those leading technological and scientific change in Europe and globally in order to positively influence the direction and objectives of their actions. This includes leaders in the commercial, research and governmental sectors

To this end, members of the European Society of Oncology Pharmacy (ESOP) consequently **determine** to produce an outline future-focused summary of:

- the primary technological and scientific drivers of change for oncology pharmacy in the next decade;
- reflections on both the opportunities, as well as any potential unintended threats, they pose for improving outcomes for cancer patients; and,
- guidance to pharmacists, companies, research institutions and policy makers on the correct means of responding to the advances in science and technology in order to drive oncology pharmacy to new levels of contribution to patient outcome and safety.

○ **The report will be developed in consultation with the ESOP membership and wider stakeholder community, with an interim publication at the ESOP members' meeting in September 2019 and final publication by ECOP 5 in 2020.**